Intersouth Partners

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

MaxCyte, Inc. is a cell-based therapies and life sciences company engaged in the development and commercialization of innovative cell modification technologies. Founded in 1998 and headquartered in Gaithersburg, Maryland, MaxCyte specializes in scalable transfection systems, including the MaxCyte STX for primary cells and stem cells, and the MaxCyte VLX for large volume applications. The company's proprietary flow electroporation platform enables the engineering of various cell types for therapeutic development, particularly in areas such as cancer immunotherapy. Additionally, MaxCyte offers single-use sterile processing assemblies and electroporation buffers, along with its ExPERT brand of instruments and consumables. The company is also advancing its CARMA technology for developing non-viral, human messenger RNA-based chimeric antigen receptor therapies. MaxCyte generates revenue through the sale and licensing of its instruments and technology to drug developers and biopharmaceutical companies, including a clinical and commercial license agreement with Allogene Therapeutics.